Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials

Quality of Life Research

Volumn 21, Issue 2, 2012, Pages 311-321

  Revicki, Dennis A ^a   Stull, Donald ^a   Vernon, Margaret ^a   Rader, Michael ^b   Tomita, Dianne ^c   Viswanathan, Hema N ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Nyack Hospital   (United States)

^c AMGEN INC   (United States)

Author keywords

Chemotherapy induced anemia; Clinical trials; Darbepoetin alfa; Fatigue; Latent growth curve modeling

Indexed keywords

ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGED; ANEMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; FATIGUE; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; ANEMIA; ERYTHROPOIETIN; FATIGUE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84863625051     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-011-9946-z     Document Type: Article

References (36)

1. Ashbury, F. D., Findlay, H., Reynolds, B., & McKerracher, K. (1998). A Canadian survey of cancer patients' experiences: Are their needs being met? Journal of Pain and Symptom Management, 16(5), 298-306. (Pubitemid 28545910)
2. Cella, D., Davis, K., Breitbart, W., & Curt, G. (2001). Cancerrelated fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology, 19(14), 3385-3391. (Pubitemid 32642191)
3. Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004). The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results: from five randomized clinical trials. Annals of Oncology, 15(6), 979-986. (Pubitemid 39004357)
4. Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition. Oncologist, 5(5), 353-360.
5. Irvine, D., Vincent, L., Graydon, J. E., Bubela, N., & Thompson, L. (1994). The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nursing, 17(5), 367-378. (Pubitemid 24300143)
6. Stone, P., Richards, M., A'Hern, R., & Hardy, J. (2000). A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Annals of Oncology, 11(5), 561-567. (Pubitemid 30431378)
7. Cella, D., Dobrez, D., & Glaspy, J. (2003). Control of cancerrelated anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Annals of Oncology, 14(4), 511-519. (Pubitemid 41295077)
8. Chang, J., Couture, F., Young, S., McWatters, K. L., & Lau, C. Y. (2005). Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Journal of Clinical Oncology, 23(12), 2597-2605. (Pubitemid 46179448)
9. Crawford, J., Cella, D., Cleeland, C. S., Cremieux, P. Y., Demetri, G. D., Sarokhan, B. J., et al. (2002). Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 95(4), 888-895. (Pubitemid 34839682)
10. Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001). Clinical evaluation of onceweekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19(11), 2875-2882. (Pubitemid 32538197)
11. Gabrilove, J. L., Perez, E. A., Tomita, D. K., Rossi, G., & Cleeland, C. S. (2007). Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapyinduced anemia: Results: of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 micro g every 2 weeks. Cancer, 110(7), 1629-1640. (Pubitemid 47463079)
12. Glaspy, J. A., Jadeja, J. S., Justice, G., Kessler, J., Richards, D., Schwartzberg, L., et al. (2002). Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer, 87(3), 268-276.
13. Johansson, J. E., Wersall, P., Brandberg, Y., Andersson, S. O., & Nordstrom, L. (2001). Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer-a randomized study. Scandinavian Journal of Urology and Nephrology, 35(4), 288-294. (Pubitemid 32906850)
14. Kallich, J. D., Tchekmedyian, N. S., Damiano, A. M., Shi, J., Black, J. T., & Erder, M. H. (2002). Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park), 16(9 Suppl 10), 117-124.
15. Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results: of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11), 2865-2874. (Pubitemid 32538196)
16. Osterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., et al. (2002). Randomized, doubleblind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. Journal of Clinical Oncology, 20(10), 2486-2494. (Pubitemid 34525734)
17. Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., et al. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology, 26(1), 132-149.
18. Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A. B., et al. (2003). Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39(14), 2026-2034. (Pubitemid 37297759)
19. Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M. H., Schipperus, M. R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal Haematology, 122(3), 394-403. (Pubitemid 36951623)
20. Littlewood, T. J., Kallich, J. D., San Miguel, J., Hendricks, L., & Hedenus, M. (2006). Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management, 31(4), 317-325.
21. Pirker, R., Ramlau, R. A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., et al. (2008). Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26(14), 2342-2349.
22. Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94(16), 1211-1220. (Pubitemid 34993871)
23. Minton, O., Stone, P., Richardson, A., Sharpe, M., & Hotopf, M. (2008). Drug therapy for the management of cancer related fatigue. Cochrane Database System Review, (1), CD006704.
24. Ross, S. D., Allen, I. E., Henry, D. H., Seaman, C., Sercus, B., & Goodnough, L. T. (2006). Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapyinduced anemia: A systematic review of the literature. Clinical Therapy, 28(6), 801-831. (Pubitemid 44062692)
25. Bollen, K., & Curran, P. (2006). Latent curve models: A structural equation perspective. Hoboken, NJ: Wiley.
26. Duncan, T., Duncan, S., & Strycker, L. (2006). An introduction to latent variable growth curve modeling: Concepts, issues, and applications. Mahwah, NJ: Lawrence Erlbaum Associates.
27. Kline, R. B. (2010). Principles and practice of structural equation modeling. New York: Guilford Press.
28. Stull, D. E. (2008). Analyzing growth and change: Latent variable growth curve modeling with an application to clinical trials. Quality of Life Research, 17(1), 47-59.
29. Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337-343. (Pubitemid 32675374)
30. Cella, D. (1997). The functional assessment of cancer therapyanemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Seminars in Hematology, 34(3 Suppl 2), 13-19. (Pubitemid 27319140)
31. Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H., & Merkel, D. E. (2002). Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24(6), 547-561. (Pubitemid 36120443)
32. Wothke, W. (2000). Longitudinal and multi-group modeling with missing data. In T. D. Little, K. Schnabel, & J. Baumert (Eds.), Modeling longitudinal and multilevel data: Practical issues, applied approaches, and specific examples. Mahwah, NJ: Lawrence Erlbaum Associates.
33. Muthén, L. K., & Muthén, B. O. (1998-2007). Mplus user's guide. Los Angeles, CA: Muthén & Muthén.
34. Browne, M., & Cudeck, R. (1993). Alternative ways of assessing model fit. In K. Bollen & J. Long (Eds.), Testing structural equation models (pp. 136-162). Newbury Park, CA: Sage.
35. Marsh, H. W., Hau, K. T., & Wen, Z. (2004). In search of golden rules: comment on hypothesis-testing approaches to setting cutoff values for fit indexes and dangers of overgeneralizing Hu and Bentler's (1999) findings. Structural Equation Modeling, 11, 320-341. (Pubitemid 38874703)
36. Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102-109.